453 related articles for article (PubMed ID: 33203661)
21. Construction of a Promising Tumor-Infiltrating CD8+ T Cells Gene Signature to Improve Prediction of the Prognosis and Immune Response of Uveal Melanoma.
Sun Y; Wu J; Yuan Y; Lu Y; Luo M; Lin L; Ma S
Front Cell Dev Biol; 2021; 9():673838. PubMed ID: 34124058
[TBL] [Abstract][Full Text] [Related]
22. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
23. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C
Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222
[TBL] [Abstract][Full Text] [Related]
26. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
[TBL] [Abstract][Full Text] [Related]
27. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.
Xia F; Yu Z; Deng A; Gao G
Exp Biol Med (Maywood); 2022 Feb; 247(3):246-262. PubMed ID: 34743576
[TBL] [Abstract][Full Text] [Related]
28. Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy.
Lv X; Ding M; Liu Y
Front Immunol; 2022; 13():848455. PubMed ID: 35309331
[TBL] [Abstract][Full Text] [Related]
29. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma.
Bronkhorst IH; Vu TH; Jordanova ES; Luyten GP; Burg SH; Jager MJ
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5370-8. PubMed ID: 22743317
[TBL] [Abstract][Full Text] [Related]
30. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
31. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
33. SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
Tanagala KKK; Morin-Baxter J; Carvajal R; Cheema M; Dubey S; Nakagawa H; Yoon A; Cheng YL; Taylor A; Nickerson J; Mintz A; Momen-Heravi F
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600652
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma.
Hu Y; Cai J; Ye M; Mou Q; Zhao B; Sun Q; Lou X; Zhang H; Zhao Y
Front Immunol; 2022; 13():1037128. PubMed ID: 36466923
[TBL] [Abstract][Full Text] [Related]
35. KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma.
Zhang J; Zhang J; Guan J; Yu L; Yan S
Dis Markers; 2022; 2022():1930185. PubMed ID: 36046379
[TBL] [Abstract][Full Text] [Related]
36. Exploring the role of BAFF as biomarker in the detection of uveal melanoma metastases.
Lin Z; Süsskind D
J Cancer Res Clin Oncol; 2021 May; 147(5):1389-1405. PubMed ID: 33665679
[TBL] [Abstract][Full Text] [Related]
37. Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma.
Zhang F; Deng Y; Wang D; Wang S
Sci Rep; 2022 Jan; 12(1):1640. PubMed ID: 35102195
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.
de Lange MJ; van Pelt SI; Versluis M; Jordanova ES; Kroes WG; Ruivenkamp C; van der Burg SH; Luyten GP; van Hall T; Jager MJ; van der Velden PA
Oncotarget; 2015 Nov; 6(35):37824-35. PubMed ID: 26462151
[TBL] [Abstract][Full Text] [Related]
39. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.
Gide TN; Paver EC; Yaseen Z; Maher N; Adegoke N; Menzies AM; Pires da Silva I; Wilmott JS; Long GV; Scolyer RA
Oncoimmunology; 2023; 12(1):2261248. PubMed ID: 37808404
[TBL] [Abstract][Full Text] [Related]
40. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
